Cytomegalovirus (CMV) remains the most common single infective cause of death following allogeneic bone marrow transplantation (BMT) from major histocompatibility complex (MHC)-identical siblings, whereas Epstein-Barr virus (EBV)-related disease is infrequent. We show here that MHC-unrestricted cytotoxic effector cells in the peripheral blood of BMT recipients are highly effective at killing EBVinfected target cells, but are inactive against CMV-infected target cells. Differential cytotoxicity is associated with disparate target structure expression. Although both EBV-and CMV-infected target cells express viral antigens, it is only those infected with EBV that express the adhesion molecule lymphocyte function-associated antigen 1 (LFA1; C D l l a / 18). Thus, EBV-infected target cells are able t o interact with the principal LFAl ligand, intercellular adhesion molecule 1 (ICAM1; CD54). which is expressed on posttransplant peripheral blood mononuclear (PBM) effector cells. CMV-infected
YTOMEGALOVIRUS (CMV) and Epstein-Barr vi-
C rus (EBV) are ubiquitous herpesviruses that generally cause only mild symptoms in normal individuals. EBV-related disease is uncommon following conventional allogeneic bone marrow transplantation (BMT) between major histocompatibility complex (MHC)-identical siblings, with few reports in the world literature of EBV-positive B-cell lymphomas.' In contrast, CMV reactivation remains the most common single cause of infective death following BMT.2-4 The most serious manifestation of CMV reactivation post-BMT is CMV pneumonia, which carries a case fatality rate of up to 85%. 3 Cellular defense against herpesviruses is mediated by MHC-unrestricted effector cells5 and by MHC-restricted virus-specific T cell^.^,^ Although cytotoxic effector lymphocytes are among the first regenerating cells to appear in peripheral blood following BMT,8 few of these are virusspecific MHC-restricted cytotoxic T lymphocyte~.~J~ In contrast, MHC-unrestricted effector cells (natural killer [NK] ) with an activated pattern of cytotoxicity regenerate early after BMT.11J2 Although these lymphocytes can kill a range of tumor-and EBV-infected target cells, there are no data comparing the efficacy of these MHC-unrestricted defense mechanisms against CMV-and EBV-infected target cells following BMT.
To determine if differences in the frequency of reactivation of these two herpesviruses were related to differences in the efficacy of cytotoxic control mechanisms, we compared MHC-unrestricted cytotoxic activity posttransplant against MHC-matched and MHC-mismatched CMVinfected marrow fibroblasts with activity directed against EBV-infected B-lymphoblastoid cell lines (B-LCL). I3 Although nonproductive CMV infection can be achieved in several hematopoietic human tissues, including peripheral blood lymphocyte^,^^ bone marrow fibroblasts were chosen as the CMV target cells, since fully permissive and target cells cannot utilize this ligand. Posttransplant cytotoxicity against EBV-infected target cells is abolished by target and effector cell blockade with monoclonal antibodies (MoAbs) t o LFAl and ICAM1, respectively, demonstrating the functional relevance of this additional ligand interaction. These results provide an illustration both of the importance and of the limitations of MHC-unrestricted cytotoxicity in vivo and may explain the frequency of CMV disease and the relative rarity of EBV-related disease following allogeneic transplantation from MHC-matched siblings. The increased immunosuppression used following MHC-mismatched/ matched unrelated-donor BMT may cause this MHC-unrestricted defense mechanism t o fail and may contribute t o the greatly increased incidence of EBV lymphoproliferative syndrome in these patients.
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productive infection is largely confined to fibroblasts. In addition, marrow fibroblasts represent a clinically relevant target, as CMV replication in bone marrow fibroblasts may explain the hematopoietic inhibition that frequently accompanies CMV reactivation p~sttransplant,~~-~* and may also underlie the delay in engraftment associated with CMV reacti~ation.~,'~ Similarly, B-LCL were chosen as the EBV target, as B cells are the dominant cell type in which EBV infection can be demonstrated during primary infection, and because posttransplant EBV-positive lymphomas arise from EBV-positive B cells. ' Cell surface adhesion molecules have recently been shown to participate in a number of intercellular interactions that are fundamental to the generation of functional immune responses?OS2l Such interactions are particularly important in the generation of MHC-unrestricted cytotoxicity.21*22 Thus, increases in NK cell adhesion molecule 3060 DUNCOMBE ET AL expression were associated with enhanced formation of effectorharget cell conjugates, enhanced killing of NKsensitive target cells and the induction of cytotoxicity for previously NK-resistant target cells.21 Intercellular adhesion molecule 1 (ICAMl; CD54) is a membrane-bound glycoprotein which is weakly expressed on resting lymphocytes, but strongly expressed on activated lymphocytes, and which is functionally important in mediating cellular cytotoxicity of target ~ells.2~ Lymphocyte function-associated antigen 1 (LFA1; CDlla/l8) is the principal ligand of ICAMIN and absence of cell surface LFAl has been proposed as a mechanism of escape from immuno~urveil~ance.~~ Furthermore, the principal ligand, ICAM1, may be particularly important in interactions with virally infected target cells, since lack of induction of cell adhesion molecules ICAMl and LFA3 has recently been proposed to explain the finding that EBV-positive Burkitt's lymphoma cell lines are not recognized by virus-specific T-cell surveillance in assays where EBV-infected LCL derived from normal B cells of the same patients are clearly r e c~g n i z e d .~. ~~ We provide evidence here of differential MHC-unrestricted cytotoxic sensitivity post-BMT between cells infected with the two herpesviruses, CMV and EBV. We show how this difference is related to target cell surface expression of adhesion molecules and we suggest that this disparity may explain the different pathogenicity of the two viruses following BMT.
MATERIALS AND METHODS

Patient details.
Eighteen recipients of BMTs for hematological malignancies and their normal donors were studied. Thirteen patients received HLA-matched sibling allografts and five received autografts. Seven patients were transplanted for acute myeloid leukemia (AML), five for common acute lymphoblastic leukemia (c-ALL), four for T-cell acute lymphoblastic leukemia (T-ALL), one for B-cell acute lymphoblastic leukemia (B-ALL), and one for ALL of undetermined subtype. Their ages ranged from 10 to 44 years (mean, 26). Recipients were conditioned with cyclophosphamide 60 mg/kg X 2 plus mesna, if they were in first remission, or with cyclophosphamide 45 mg/kg x 2 and cytosine arabinoside 2 g/m2 twice daily for 3 days if they were in second remission. In addition, all patients received single-dose total body irradiation at a maximum prescribed dose of 750 cGy to the lungs at a dose rate of 15 2 2 cGy/min?8
Allograft patients received HLA-identical sibling marrow depleted of T cells in vitro by specific antibody followed by complement-mediated lysis.28 The mean T-cell depletion was 96.2%, and the mean number of T cells infused was 7.1 x 1@/kg. No routine posttransplant immunosuppression was administered. For autograft patients, cryopreserved autologous marrow was purged in vitro with a combination of CDlO and CD19 antibodies for patients with c-ALL, with CD7 antibody for patients with T-ALL, and with CD19 antibody for the patient with B-ALL. The incidence of graft-versus-host disease (GVHD) in all was low, as previously reported with T-cell-depleted allografts,28 and only a single allograft recipient had acute GVHD (grade 111) at the time of study. Three allograft recipients had mild and limited chronic GVHD of skin at the time of study. All had been preceded by acute GVHD, grades I, 11, and 111, respectively. Therapy for GVHD was with steroids: methylprednisolone at 1 g, rapidly reducing for acute GVHD, and at a dose of 1 to 1.5 mg/kg for chronic GVHD.
However, none of the recipients with chronic GVHD were on treatment at the time of study.
Eight of the allograft recipients were seropositive for CMV and five were seronegative. Of the allograft donors, eight were seropositive and five seronegative. All five autograft recipients were seropositive. Two allograft recipients in the study developed CMV disease from which they both died. One patient had pneumonitis at the time of study, which proved rapidly fatal and which was shown to be due to CMV at postmortem examination. A further allograft recipient, who was well at the time of study, developed a fulminant fatal CMV hepatitis 1 month later.
Iliac crest bone marrow was harvested under sterile conditions into heparin (10 U/mL) from recipients prior to conditioning and from their normal donors on the day of transplant. Marrow was diluted 1:2 with McCoy's 5A medium (Flow Laboratories, Rickmansworth, Herts, UK) containing 2.20 g/L sodium bicarbonate supplemented with L-glutamine (2 mmol) and penicillin/streptomycin (100 U/mL) and layered in 10-mL aliquots on 10 mL Lymphoprep (Nyegaard, Oslo, Norway). After centrifugation at 400 x g for 30 minutes, interface cells were washed and resuspended at 2 x lo6 cells/mL in McCoy's 5A medium supplemented as above containing 10% fetal calf serum (FCS) screened for optimal growth of fibroblast cell lines. Cells were incubated in tissue culture flasks at 37°C in 5% C02. After 24 hours, the medium was decanted to discard nonadherent cells and replaced with fresh medium. Flasks were incubated to confluence (1 to 3 weeks), after which the cell layer was passaged by trypsinization. All adherent cells used in assays were between first and third passage.
Immunohistochemisny of marrow adherent cell layer. Aliquots of passaged adherent cells were grown onto glass slides to confluence and fixed in formalin for 30 minutes. An avidin-biotin complex (ABC) immunoperoxidase technique was performed with hematoxylin counterstain using mouse monoclonal antibodies (MoAbs). MoAbs used were ( The substrate 3,3-Diaminobenzidine (DAB) was added after washing, and after a further rinse in TBS, the slides were counterstained in Mayer's hematoxylin, dehydrated, and mounted.
CMV strain AD169 was propagated on a human embryonic lung cell line (HEL) screened for absence of bacterial, fungal, and mycoplasmal contamination. Virus was halvested from the culture fluid, clarified by centrifugation at 500 x g, and stored at -70°C until use. Virus preparations were titrated in 10-fold dilutions in quadruplicate and inoculated onto bone marrow fibroblast monolayers in 96-well microtiter plates. Wells were observed after 14 days culture at 37°C in 5% C02 for the occurrence of cytopathic effect (cpe) and the minimum virus dose that caused cpe in 50% of the wells, the TCIDs,-,, was calculated by the Kaerber method.29 The virus stocks used had an infectivity of 6.3 x 108 TCIDso U/mL on marrow fibroblasts.
For each assay, two culture flasks of similar subconfluence were chosen. After washing, 1 mL of virus Fibroblast culture.
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was added to one flask, which was then incubated for 1 hour at 37°C in 5% COz. Virus was aspirated and replaced with McCoy's 10% FCS. A second flask was used as an uninfected control by washing and replacement with control medium. Cells were incubated for 48 to 72 hours at 37°C in 5% COz before cytotoxicity assays.
This was performed according to a standard te~hnique.'~ Peripheral blood mononuclear cells (PBM) were obtained by centrifugation on Lymphoprep from venepunctures of posttransplant patients and normal controls. With three exceptions, recipient samples were obtained between 3 and 8 weeks post-BMT-the period previously shown for peak MHC-unrestricted cytotoxicity against EBV-infected LCL target cells.11.30 However, three allograft recipients were tested later, at 34, 48, and 70 weeks posttransplant, respectively. Effector cells were suspended at a concentration of 5 x 1@/mL in RPMI 1640 medium (Flow Labs) with 10% FCS heat-inactivated for 45 minutes at 56°C. The EBV-infected LCL was labeled by incubation with 3.7 MBq 51Cr (Amersham International PLC, Aylesbury, Bucks, LJK) for 90 minutes. CMV-infected and uninfected bone marrow fibroblasts, prepared as above, were trypsinized, washed, and resuspended to 200 FL with neat FCS and labeled by incubation with 3.7 MBq 51Cr for 40 minutes at 37°C in 5% COz. After washing twice, target cells and effectors were set up in a standard 4-hour chromium release assay with effector:target (E/T) ratios ranging from 1OO: l to 4:1?O Percentage specific lysis was calculated from the following formula: (Experimental release -spontaneous release/Maximum release -spontaneous release) X 100.
Cold target competition. This was performed using a simple modification of the chromium release assay above. Duplicate wells were set up with post-BMT PBM as effectors and radiolabeled ("hot") EBV-infected LCL target cells at an E T ratio of 100:l. Further duplicates were set up to which were added either unlabeled ("cold") EBV-infected LCL target cells or "cold" CMV-infected bone marrow fibroblasts at "cold/hot" target ratios of 5:lO and 201. For each ratio of cold/hot target ratio, percentage specific lysis was calculated as above. Percentage competition was calculated using the following formula: % competition = 100 x [(% specific lysis without competitor cells -% specific lysis with competitor cells)]/(% specific lysis without competitor cells).
Cytospin preparations of CMV-infected bone marrow fibroblasts were made immediately prior to use as target cells in the chromium release assay. Slides were fixed in acetone and examined with a panel of anti-CMV antibodies by an indirect immunofluorescence technique previously described.31 Antibodies used were as follows: (1) MoAb specific for the 72-Kd immediate early antigen; (2) MoAb (p7.17) directed against the gB CMV late antigen; and (3) MoAb cocktail recognizing several epitopes of the gB CMV late antigen. All antibodies were kind gifts of Dr W. Britt (University of Alabama, Birmingham). Slides were photographed using an epifluorescent microscope. Replicate cytospin preparations of target cells were examined for mycoplasmal contamination using the Hoechst dye staining method.32 None was found.
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microscope and were also analyzed by flow cytometry using an EPICS 2 cell analyzer (Coulter Electronics, Luton, Beds, UK).
MoAb blocking studies of effector and target cell adhesion molecules. For these studies, the effector and target cell preparation was modified as follows. Post-BMT PBM effectors (5 x 105) were incubated with 4 Fg of MoAb to ICAMl (CD54) for 15 minutes at 4"C, washed, and resuspended to a concentration of 5 x 106/mL before use in the 51Cr release assay described above. EBV-infected LCL target cells (5 X 105) were incubated with 4 Fg of MoAb to LFAl (CDlla) for 15 minutes at 4"C, washed, and resuspended to a concentration of 5 x 1@/mL before use in the 51Cr release assay. Four combinations were then tested: (1) Statistics. Statistical analysis was performed by Student t testing of paired data.
RESULTS
Purity offibroblast adherent cell layer by immunohistochemis@. All preparations stained strongly for Vimentin, the 57-Kd intermediate filament protein. In contrast, the monocyte and macrophage marker Mac-387 was present in less than 2% of cells in the adherent layer after the first passage. Tissue-specific staining was not seen for VWF, the factor VIII-related antigen expressed on endothelial cells. This demonstrates that our culture technique selected for the growth of bone marrow fibroblasts.
Minimal cytotoxic sensitivity of CMVand EBVtarget cells to MHC-unrestricted killing by normal PBM. Normal PBM show variable but generally low cytotoxicity against MHCmismatched CMV-infected bone marrow fibroblasts. Cytotoxicity ranged from 0.0% to 17.3% at an E:T ratio of 8O:l (mean -c SEM, 5.8 2 2.7). Normal PBM are consistently unable to kill MHC-mismatched EBV-infected LCL target cells (mean % cytotoxicity f SEM, 1.1 f 0.3 at E:T ratio of 8O:l) as previously demonstrated.3O
Differential cytotoxic sensitivity of CMVand EBVtarget cells
to MHC-unrestricted killing by posttransplant PBM. After BMT, this pattern is altered. With a single exception, all BMT patients showed less than 5% specific cytotoxicity against MHC-mismatched CMV-infected marrow fibroblasts at E:T ratio of 8O:l (Fig 1) . Similarly, cytotoxicity of posttransplant PBM against MHC-matched CMV-infected marrow fibroblasts was also low (mean % specific W r release 2 SEM, 1.45 2 1.32 at E:T ratio of 801), indicating lack of MHC-restricted cytotoxicity in this system. Specific cytotoxicity against CMV-infected target cells was consistently less than 5% in allograft recipients with and without GVHD and in the two patients who subsequently died of CMV disease. Furthermore, killing of CMV-infected target cells was also less than 5% in the three allograft recipients studied later posttransplant at 34, 48, and 70 weeks, respectively, indicating MHC-unrestricted cytotoxicity against CMV targets is not apparent to at least 70 weeks post-BMT. In contrast, substantial killing of MHCmismatched EBV-infected LCL target cells was seen (mean cytotoxicity 2 SEM, 33.3 5 7.5 at E:T ratio of 80:1, P < .001) (Fig 1) . No increase in cytotoxicity was seen against MHC-matched EBV-infected LCL, demonstrating no evidence of MHC-restricted cytoto~icity.3~
The difference between EBV and CMV cytotoxic sensitivity post-BMT is due to disparate target structure expression. To determine whether failure to kill CMV-infected marrow fibroblasts was associated with failure to express the target structures recognized by MHC-unrestricted cytotoxic cells, unlabeled CMV-infected marrow fibroblasts or EBVinfected LCL were added in increasing numbers to 51Cr-labeled EBV-infected LCL target cells in cold target inhibition studies. In the presence of a constant number of patient effector cells, unlabeled EBV-infected LCL competed effectively with Wr-labeled EBV-infected LCL (Fig  2) . In contrast, unlabeled CMV-infected marrow fibroblasts competed poorly against 5ICr-labeled EBV-infected LCL (Fig 2) , implying that the difference between EBV and CMV cytotoxic sensitivity post-BMT is due to differences in expression of target structures.
Failure to kill was not due to inadequate viral infection. Although it is probable that MHC-unrestricted killer cells recognize cellular surface antigens that are not of viral 0rigin,3~,~~ an alternative explanation for failure to kill CMV-infected target cells is that the cells express no viral antigens. However, cytospin preparations of CMV-infected marrow fibroblasts prepared immediately before use as target cells in the chromium release assay showed that the 72-Kd immediate early antigen was present on more than 90% of the cells (see Methods). Furthermore, CMV "late" antigens were expressed on more than 85% of target fibroblasts.
EBV and CMV target cells differ in their surface expression of LFAI. To determine whether differences in surface expression of adhesion molecules could explain the differential MHC-unrestricted cytotoxicity between EBV and CMV target cells, we analyzed expression of LFAl (CDlla/l8), LFA3 (CD58), ICAMl (CD54), and CD2 on EBV and CMV target cells immediately before use in our W r release assay by indirect immunofluorescence and flow cytometry (see Methods). ICAMl and LFA3 were expressed on both target cells (Fig 3A and B) , while CD2 was expressed on neither. In contrast, however, LFAl was expressed only on EBV target cells (Fig 3A) and was absent on CMV target cells (Fig 3B) . This difference provides EBV target cells with an additional binding ligand compared with CMV target cells, since posttransplant effector cells express surface ICAMl (Fig 4) .
Cytotoxicity against EBV-infected target cells is inhibited by
blockade of target cell LFAl and effector cell ICAMI. If LFA1-ICAM1 ligand interaction is indeed functionally important in determining cytotoxic sensitivity, then blockade of these ligands by MoAbs against target cell LFAl and effector cell ICAMl should abrogate cytotoxicity. Such an effect has been shown in T-cell-mediated antiviral cytotoxicity3' and we show here that this also occurs in MHCunrestricted cytotoxicity against viral-infected target cells. disease and EBV-related disease after MHC-identical sibling transplant BMT parallels differences in the capacity of regenerating cells post-BMT to destroy the physiological target cells for the two herpesviruses and suggest that these observations may be causally related.
Among the earliest recovering effector cells following BMT are CD16+/CD3-and CD16-/CD3+ activated killer cells demonstrating high levels of cytotoxicity to EBVinfected LCL target cells as measured in a short chromium release assay (Fig 1) .11J2 Such target cells are not sensitive to killing by normal PBM (see The explanation for this "activated killing" of EBV-infected target cells after autologous and allogeneic transplant is unknown. However, GVHD is not responsible for the high levels of MHCunrestricted cytotoxicity seen in this early posttransplant period, and there is no significant difference in the magnitude of such cytotoxicity between autograft and allograft re~ipients.ll,~~ Despite uncertainty over the precise nature of the activating stimulus, the nature of the mediators of this response is now known." Direct cytotoxicity against EBV-infected LCL posttransplant appears to be predominantly mediated by the CD16+/CD3-subset, although substantial activity remains in the CD16-/CD3+ fraction."
In contrast, levels of direct cytotoxicity against MHCmatched or MHC-mismatched CMV-infected target cells are low posttransplant (Fig 1) . This lack of cytotoxicity does not appear to reflect the time posttransplant at which they were tested. Thus, while most samples were assayed between 3 and 8 weeks following BMT to coincide with the period of peak MHC-unrestricted cytotoxic activity, three allograft recipients who were assayed at 34, 48, and 70 weeks posttransplant, respectively, also showed lack of cytotoxicity of MHC-matched CMV-infected targets. This is in contrast to EBV-infected targets, for which allograft recipients begin to show MHC-restricted cytotoxic responses by 6 months post-BMT? Nevertheless, our assays were performed using fresh cells, in contrast to the method of prolonged in vitro incubation with interleukin-2 and coculture with irradiated stimulator cells. As the latter system is the most sensitive assessor of MHC-restricted cytotoxicity, we cannot exclude the return of MHCrestricted cytotoxicity against CMV targets after a similar 6-month period posttransplant. However, we have shown that the failure of MHC-unrestricted cytotoxicity against CMV-infected target cells persists to at least 70 weeks Discrepant reports on the role of CMV infections and activated killing posttransplant have been r e p~r t e d .~~,~~ Some investigators found a strong ass0ciation,3~ while others found no clear r e l a t i~n s h i p . ~~ We have found no induction of MHC-unrestricted cytotoxicity against CMV targets in recipients with GVHD or in recipients who subsequently died of CMV disease. Although the magnitude of the cytotoxicity observed against EBV-infected targets varied among individual recipients, cytotoxicity was substantially greater against EBV-than CMV-infected target cells in all patients. Indeed, only one recipient showed greater than 5% specific cytotoxicity against MHCmismatched or MHC-matched CMV-infected marrow fibropost-BMT.
blasts. This patient was in first complete remission of T-ALL and was the recipient of an autograft purged in vitro with anti-CD7 antibody. He displayed specific cytotoxicity against MHC-mismatched CMV-infected marrow fibroblasts of 34% at an E:T ratio of 8O:l. The explanation of this isolated case of substantial cytotoxicity against CMVinfected target cells remains unclear. Nevertheless, even in this patient, the differential cytotoxicity between the two virally infected targets was preserved, since the specific cytotoxicity against the EBV-infected target was 79%. This lack of MHC-unrestricted cytotoxicity against CMV target cells appears to conflict with an earlier report.@ However, in contrast to our standard 4-hour chromium release assay, this study used a long 18-hour chromium release assay in which cytotoxic cytokine release is likely to augment the effect of direct cellular cytotoxicity. Indeed, using normal PBM, MHC-unrestricted cytotoxicity against CMV-infected target cells has been demonstrated in long chromium release assays (18 to 20 hours), but not in short assays of 6 to 8 hours' d~r a t i o n . "~,~~ We have also confirmed this observation (data not shown).
We have demonstrated that lack of MHC-unrestricted direct cytotoxicity to CMV-infected marrow fibroblasts was not due to inadequate CMV infection. Strongly positive fluorescence was seen on cytospin preparations of target cells for the 72-Kd immediate early antigen and the gB CMV late antigen (see Results). Nor is failure to kill due to the absence of HLA-DR-positive accessory cells in the effector population. Although these cells have been shown to be required for MHC-unrestricted cytotoxicity of CMVinfected fibroblast^:^ they are present in post-BMT PBM in normal numbers. 44 Instead, differences in MHC-unrestricted killing are likely to represent differences in expression of target structures involved in intercellular adhesion. A number of molecules recognized by CD16+ and CD3+ MHC-unrestricted cytotoxic effectors on viral and tumor target cells have been identified.20-4s.4 Since reciprocal inhibition between herpes simplex virus (HSV)-infected and uninfected fibroblasts has been dem~nstrated?~ it is likely that the target structure on infected cells recognized by MHCunrestricted effectors is not encoded by virus. As we observed low levels of cytotoxicity against CMV target cells in our 4-hour chromium release assay, we were unable to assess the inhibition of CMV-infected target cells in competitive assays. Instead, we used the high levels of cytotoxicity against EBV-infected LCL to assess target structure competition by CMV-infected marrow fibroblasts. The lack of competition (Fig 2) strongly suggested that disparate expression of target molecules may explain the observed differential MHC-unrestricted sensitivity.
What is the nature of these target molecules? A number of structures have been proposed, including the transferrin r e~e p t o r~~,~~ and HLA class I molecule^.^^^^ Our attention turned to the surface adhesion molecules, in particular LFA1, since absence of cell surface LFAl has been proposed as a mechanism of escape from immunosurveillance. 25 We have shown here that EBV-infected LCL express surface LFA1, while CMV-infected marrow fibro-blasts do not (Fig 3A and B) . Since ICAMl is present on circulating PBM effector cells post-BMT (Fig 4) , there is an additional receptor-ligand interaction between EBV target cells and effector cells that cannot occur between CMV target cells and effector cells. Our observation on the functional importance of this ligand interaction (Fig 5) parallels that of other investigators in different systems. ICAMl/LFAl interaction has been shown to be important in antigen-independent conjugate formation, antigenspecific cytotoxic T-lymphocyte recognition, and cytolysis of a variety of target cells, including EBV-infected LCL." This ligand pair also participates in the adhesive interaction between monocytes and T lymphocytes involved in the initiation of the immune response.48 ICAMl /LFA1 interactions have been shown to be important in mediating NK cell responses in normal and we now show their functional importance in MHC-unrestricted cytotoxicity against viral-infected target cells following BMT.
Thus, our observation that CMV-infected fibroblasts are not vulnerable to direct killing by circulating effector cells post-BMT while EBV-infected LCL are readily killed may explain both the frequency of CMV reactivation and disease and also the rarity of EBV-related disease following MHC-identical sibling BMT. However, EBV-dependent lymphoproliferative syndrome (EBV-LP) is much more common after MHC-mismatched or -matched unrelateddonor allografts, where the incidence may reach 25%. We suggest that the increased risk of EBV-LP after mismatched/ unrelated-donor allografts is a consequence of the more intensive pretransplant and posttransplant immunosuppression given to these patients to reduce rejection and the risk of severe GVHD. It would be of interest to see if the MHC-unrestricted effector mechanisms we have described are impaired in these patients and are unable to kill either EBV-or CMV-infected target cells.
